Oncodesign Precision Medicine (XPAR:ALOPM) Cash, Cash Equivalents, Marketable Securities : €1.50 Mil (As of Jun. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Cash, Cash Equivalents, Marketable Securities?

Oncodesign Precision Medicine's quarterly cash, cash equivalents, marketable securities declined from Dec. 2020 (€8.43 Mil) to Dec. 2021 (€4.92 Mil) but then stayed the same from Dec. 2021 (€4.92 Mil) to Jun. 2022 (€1.50 Mil).

Oncodesign Precision Medicine's annual cash, cash equivalents, marketable securities increased from . 20 (€0.00 Mil) to Dec. 2020 (€8.43 Mil) but then declined from Dec. 2020 (€8.43 Mil) to Dec. 2021 (€4.92 Mil).

Oncodesign Precision Medicine Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Oncodesign Precision Medicine's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Cash, Cash Equivalents, Marketable Securities Chart

Oncodesign Precision Medicine Annual Data

Trend

Dec20

Dec21

Cash, Cash Equivalents, Marketable Securities

8.43

4.92

Oncodesign Precision Medicine Semi-Annual Data
	Dec20	Dec21	Jun22
Cash, Cash Equivalents, Marketable Securities	8.43	4.92	1.50

Oncodesign Precision Medicine Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Oncodesign Precision Medicine (XPAR:ALOPM) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Oncodesign Precision Medicine Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 rue Jean Mazen, Dijon, FRA, 21000

Website

https://www.opm.oncodesign.com

Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines